Physician profile
Timothy J Miller
NPI 1073882189
$8,478.71
in general payments reported to CMS, 2019-2025
40 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $401 · 2021: $1,254 · 2022: $1,552 · 2023: $1,600 · 2024: $1,576 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,247.82 | 2021-2025 | |
| Novo Nordisk INC | $1,155.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $662.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $658.46 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $627.20 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.18 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.54 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $274.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $268.62 | 2022-2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $220.95 | 2022-2025 | |
| Axsome Therapeutics, INC. | $192.12 | 2023-2025 | Auvelity |
| Daiichi Sankyo INC. | $167.54 | 2020-2025 | Injectafer |
| Amgen INC. | $163.19 | 2021-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $157.70 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $150.29 | 2023-2025 | Rexulti |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $126.16 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $120.35 | 2022 | |
| Indivior INC. | $118.85 | 2019-2025 | Sublocade |
| Dexcom, INC. | $114.74 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $112.34 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $104.43 | 2021 | |
| Lundbeck LLC | $102.76 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $100.76 | 2020-2021 | |
| Exact Sciences Corporation | $96.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $95.99 | 2024-2025 | Korlym |
| Alkermes, INC. | $87.53 | 2019-2025 | Vivitrol |
| Inspire Medical Systems, INC. | $56.66 | 2024-2025 | Inspire |
| Verona Pharma, INC. | $56.55 | 2025 | Ohtuvayre |
| Endologix LLC | $45.94 | 2024 | Torus Stent Graft System, Endocross Device |
| Ucb, INC. | $42.02 | 2023-2024 | Nayzilam |
| Grt US Holding, INC. | $37.39 | 2022 | |
| Mylan Specialty L.P. | $36.38 | 2021-2024 | Yupelri |
| Ironshore Pharmaceuticals INC. | $29.95 | 2022-2023 | Jornay Pm |
| Abbott Laboratories | $23.61 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $19.53 | 2020 | |
| Electromed, INC. | $19.24 | 2025 | Smartvest |
| Neurelis, INC. | $17.27 | 2023 | Valtoco |
| Bausch Health US, LLC | $16.81 | 2022 | |
| Insulet Corporation | $15.95 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.